Tofacitinib (11 mg) Extended Release Tablet | PCD Pharma Manufacturer & Supplier India | Trumac Healthcare
Tofacitinib (11 mg) Extended Release Tablet
WHO-GMP Manufacturer & PCD Pharma Franchise Supplier in India
Form: Tablet
Class: JAK1/3 inhibitor (Extended Release, once-daily DMARD)
✓ Pan-India Monopoly PCD
✓ 2 Brand Options
Pricing, brochure & monopoly territory within 24 hrs.
Our Tofacitinib (11 mg) Extended Release Tablet Brand Options (2 options)
Trumac Healthcare manufactures and supplies the following Tofacitinib (11 mg) Extended Release Tablet brands for PCD pharma distribution. Click any brand to view full specifications and packaging.
Tofacitinib (11 mg) Extended Release Tablet is manufactured under WHO-GMP-certified conditions by Trumac Healthcare and supplied for PCD/Propaganda-cum-Distribution pharma franchise on monopoly basis across India. Whether you are a PCD distributor, stockist or retail chemist, our Tofacitinib (11 mg) Extended Release formulation comes with full quality assurance, regulatory documentation and reliable pan-India despatch.
Therapeutic Indications
- Moderate-to-severe active rheumatoid arthritis
- Active psoriatic arthritis
- Moderate-to-severe ulcerative colitis
- Ankylosing spondylitis
- Polyarticular juvenile idiopathic arthritis (specialist use)
Mechanism of Action
Tofacitinib competitively binds the ATP-binding pocket of Janus kinases (mainly JAK1 and JAK3, with lesser activity at JAK2 and TYK2). This blocks STAT phosphorylation and downstream transcription of pro-inflammatory cytokines including IL-2, IL-6, IL-15, IL-21 and interferons. The result is suppression of T-cell activation, B-cell maturation, plasma-cell differentiation and synovial inflammation.
Dosage & Administration
- Adults: 1 tablet (11 mg ER) once daily, with or without food
- Swallow whole — do not crush, split or chew
- Monitor CBC, lipids, LFT periodically
- Use only as advised by a rheumatologist or gastroenterologist
Side Effects
- Increased upper-respiratory infections
- Herpes zoster reactivation
- Headache
- Diarrhoea
- Elevated cholesterol
- Anaemia / lymphopenia
Contraindications
- Active serious infection including TB
- Severe hepatic impairment
- Pregnancy and breastfeeding
- Live vaccines during treatment
- History of major thrombotic events (boxed warning)
Storage
Store below 30 °C in a dry place, protected from light and moisture.
PCD Pharma Franchise for Tofacitinib (11 mg) Extended Release Tablet
- ✓ WHO-GMP certified manufacturing facility
- ✓ Pan-India monopoly distribution rights available
- ✓ Multiple pack sizes: 10 x 1 x 10 (Alu Alu), 10 x 10 (Alu Alu)
- ✓ Trade-friendly PTR / PTS margins
- ✓ Free promotional material on request
- ✓ Full DCGI documentation and quality certificates supplied
Trumac Healthcare offers 2 brand options for Tofacitinib (11 mg) Extended Release Tablet — each available in different pack sizes with trade-friendly margins. View the brand-specific pages below for detailed specifications, MRPs and packaging options.
For PCD franchise opportunities, monopoly distribution rights, or third-party contract manufacturing of Tofacitinib (11 mg) Extended Release Tablet, contact our business development team. WhatsApp +91 9041677932 or email info@trumachealthcare.net.
Frequently Asked Questions
Who is the manufacturer of Tofacitinib (11 mg) Extended Release Tablet?
Trumac Healthcare is a WHO-GMP certified manufacturer of Tofacitinib (11 mg) Extended Release Tablet in India. We supply our own brand range (see brand options above) and also offer third-party contract manufacturing for PCD distributors.
Is Tofacitinib (11 mg) Extended Release Tablet available for PCD pharma franchise on monopoly basis?
Yes. We offer Tofacitinib (11 mg) Extended Release Tablet for PCD/Propaganda-cum-Distribution pharma franchise on monopoly basis across all districts of India. Contact our business development team for pricing and territory availability.
What pack sizes are available for Tofacitinib (11 mg) Extended Release Tablet?
Available pack sizes include: 10 x 1 x 10 (Alu Alu), 10 x 10 (Alu Alu).
What is the MRP / trade price for Tofacitinib (11 mg) Extended Release Tablet?
MRPs range from ₹3950 to ₹7950 across our brand variants. Trade-friendly PTR/PTS margins available on request — WhatsApp +91 9041677932 for current rates.
How do I place an order or franchise enquiry?
WhatsApp +91 9041677932 or email info@trumachealthcare.net with your enquiry. Our team will revert within 24 hours with full pricing, brochure and franchise terms.
Ready to start your PCD franchise for Tofacitinib (11 mg) Extended Release Tablet?